Preclinical evidence of Yinchenhao decoction on cholestasis: A systematic review and meta‐analysisof animal studies

Abstract

Cholestasis is an important cause of liver fibrosis and cirrhosis. Yinchenhao decoction has been used as a well‐known traditional Chinese medicine used in the treatment of cholestasis for over 2,000 years. The purpose of this systematic review is to evaluate the preclinical evidence of Yinchenhao decoction on cholestasis models. The following databases were searched from inception to February 2020. Chinese National Knowledge Infrastructure, VIP medicine information system, Wanfang Database, PubMed, Web of Science, Embase and the Cochrane Library were searched. The content concerned Yinchenhao decoction on different animal model experiments for the treatment of cholestasis. The methodological quality of the included studies was assessed based on the SYstematic Review Center for Laboratory animal Experimentation Animal Experiment Bias Risk Assessment Tool. A meta‐analysis was conducted with RevMan 5.3 software according to the Cochrane tool. Nineteen studies on a total of 404 animals were included with five kinds of experimental animal models. The results showed that serum total bilirubin (TBIL), direct bilirubin (DBIL), indirect bilirubin and total bile acid in the group treated with Yinchenhao decoction were significantly lower than those in the model group (P < 0.00001). The alanine aminotransferase (ALT), aspartate aminotransferase and alkaline phosphatase levels in the Yinchenhao decoction group were also significantly reduced (P < 0.00001). The subgroup analysis of the different models showed that Yinchenhao decoction had a significant effect on the bile duct ligation model, and there was a significant reduction in TBIL, DBIL and ALT levels (P < 0.00001) in ANIT‐induced cholestasis. After 24 hours of Yinchenhao decoction treatment, there was no significant difference in TBIL levels (P = 0.34), but after 48 and 72 hours of treatment, the TBIL levels were significantly reduced compared with the model group (P < 0.00001). There was no significant difference in DBIL after 48 hours of administration (P = 0.26), but compared with the model group, Yinchenhao decoction could significantly reduce the DBIL levels after 48 hours of treatment (P < 0.0003). Yinchenhao decoction could significantly reduce the ALT levels after 24, 48 and 72 hours (P < 0.006). Yinchenhao decoction was able to significantly reduce the levels of TBIL, DBIL and ALT on different rat species: Wistar and Sprague Dawley (P = 0.0001; P = 0.0002). The preclinical evidence indicated that Yinchenhao decoction might be a potent and promising agent for cholestasis. Moreover, this conclusion should be further confirmed with more well‐designed researches.

Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies

“…The emergence of heterogeneity not only deepens the content of this review but also leaves wider issues to be explored. The occurrence of heterogeneity is influenced by multi-factors, including experimental design, study subjects, intervention measures, and results combination ( Thompson et al, 1997 ; Hooijmans et al, 2014 ; Shi et al, 2021 ). The great heterogeneity difference in this review may be due to BBR and animal diets coming from different laboratories.…”

Yinchenhao decoction alleviates high‐carbohydrate diet‐induced hepatic lipids deposition by strengthening lipids metabolism and transport in largemouth bass

“…Therefore, it makes great sense for searching additive for liver health of fish fed on high‐carbohydrate diet. It was widely reported YCHD promoted lipids metabolism in human and mice (Shi et al, 2021). However, the beneficial effects of YCHD on fish lipids metabolism are still unknown.…”

“…It has been used to treat hepatic metabolism disease for more than 1800 years and has long been a very popular recipe in China and Japan (Li et al, 2017). Recent studies clearly indicated that YCHD has responsible therapeutic effects for non‐alcoholic fatty liver disease (NAFLD), significantly down‐regulate hepatic total cholesterol (TC) and triglyceride (TG), and non‐esterified fatty acid (NEFA) content (Shi et al, 2021). The active ingredients of YCHD have been identified, such as chlorogenic acid, geniposide, quercetin, anthraquinones, catechin and so on (Cho et al, 2010; Huang et al, 2017).…”

“…The active ingredients of YCHD have been identified, such as chlorogenic acid, geniposide, quercetin, anthraquinones, catechin and so on (Cho et al, 2010; Huang et al, 2017). Most of these ingredients could alleviate abnormal lipids metabolism (Cho et al, 2010; Jiang et al, 2019; Yang, Zhu, et al, 2019; Zhou et al, 2019), but the most economical and efficient therapeutic treatment is using YCHD (Shi et al, 2021).…”

Chlorogenic acid improves diabetic retinopathy by alleviating blood‐retinal‐barrier dysfunction via inducing Nrf2 activation

“…Traditional Chinese medicine (TCM) is widely applied in various chronic diseases due to its low price and fewer side effects (Ahmed et al, 2020; Shi et al, 2021). Recently, more and more attentions have been paid to the clinical application and experimental study of TCM for DR treatment (Ai et al, 2020; Ou, Yang, & Peng, 2019).…”